Li Ningcen, Wang Meijuan, Lyu Zhongxi, Shan Kai, Chen Zelin, Chen Bo, Chen Yong, Hu Xiyou, Dou Baomin, Zhang Jingyu, Wang Lifen, Zhao Tianyi, Li Hongjiao
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Pharmacol. 2023 Mar 23;14:1158945. doi: 10.3389/fphar.2023.1158945. eCollection 2023.
Inflammatory bowel disease (IBD) is a chronic recurrent intestinal disease. The incidence rate of IBD is increasing year by year, which seriously endangers human health worldwide. More and more studies have shown that medicinal plants or their main phytochemicals have great potential in the treatment of intestinal diseases. However, the disadvantages of low oral absorption rate, low biological distribution and low systemic bioavailability limit their clinical application to a certain extent. In recent years, the application of nanotechnology has made it possible to treat IBD. Nanoparticles (NPs) drug delivery system has attracted special attention in the treatment of IBD due to its small size, low immunogenicity, surface modification diversity, targeting and other advantages. Synthetic nanoparticles and extracellular vehicles (EVs) can deliver drug components to colon, and play a role in anti-inflammation, regulation of oxidative stress, improvement of intestinal flora, etc. In addition, some medicinal plants can secrete EVs by themselves, and carry biological molecules with therapeutic effects to act on the intestine. Some clinical trials to evaluate the safety, tolerance, toxicity and effectiveness of EVs-loaded drugs in IBD are also progressing steadily. This review introduces that synthetic nanoparticles and medicinal plants derived EVs can play an important role in the treatment of IBD by carrying the effective active phytochemicals of medicinal plants, and discuss the limitations of current research and future research needs, providing a scientific and reliable basis and perspective for further clinical application and promotion.
炎症性肠病(IBD)是一种慢性复发性肠道疾病。IBD的发病率逐年上升,在全球范围内严重危害人类健康。越来越多的研究表明,药用植物或其主要植物化学物质在肠道疾病治疗方面具有巨大潜力。然而,口服吸收率低、生物分布性差和全身生物利用度低等缺点在一定程度上限制了它们的临床应用。近年来,纳米技术的应用为IBD的治疗带来了可能。纳米颗粒(NPs)药物递送系统因其尺寸小、免疫原性低、表面修饰多样、靶向性等优点,在IBD治疗中受到了特别关注。合成纳米颗粒和细胞外囊泡(EVs)可以将药物成分递送至结肠,并在抗炎、调节氧化应激、改善肠道菌群等方面发挥作用。此外,一些药用植物自身能够分泌EVs,并携带具有治疗作用的生物分子作用于肠道。一些评估载有EVs的药物在IBD中的安全性、耐受性、毒性和有效性的临床试验也在稳步推进。本综述介绍了合成纳米颗粒和源自药用植物的EVs通过携带药用植物的有效活性植物化学物质在IBD治疗中可发挥重要作用,并讨论了当前研究的局限性和未来研究需求,为进一步的临床应用和推广提供科学可靠的依据和前景。